RE:RE:Collaboration with JansenI absolutely agree with KayakerBC about avoiding an "acquisition" through a Contingent Value Rights (CVR) deal. (
His post about CVRs)
Bioasis ought to be able to get at least one business deal done of sufficient value to accurately value the entire suite of xB3-enabled commercial opportunities.
Even the most modest shareholder expectations have not been met in the entire history of Bioasis. If xB3 continues to perform
as declared so far by Bioasis, then it may have the capability to enable drug/disease combinations worth tens of billions of annual commercial revenue.
Get it done.
No bailing out!
No easy answers!
Get the value that shareholders deserve and demand!
Get it up front - avoid years of delays that CVRs cause. Shareholders will wait for a deal but they won't wait for payment, not after what they've been through.
jd